Cargando…

Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways

BRAF(V600E), the most common genetic alteration, has become a major therapeutic target in thyroid cancer. Vemurafenib (PLX4032), a specific inhibitor of BRAF(V600E) kinase, exhibits antitumor activity in patients with BRAF(V600E)-mutated thyroid cancer. However, the clinical benefit of PLX4032 is of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Jingyi, Liu, Juan, Zhao, Man, Li, Xinru, Wang, Yubo, Zhao, Yuelei, Cao, Hongxin, Ji, Meiju, Chen, Mingwei, Hou, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968072/ https://www.ncbi.nlm.nih.gov/pubmed/36834830 http://dx.doi.org/10.3390/ijms24043418

Ejemplares similares

STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells
por: Li, Xinru, et al.
Publicado: (2023)

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
por: Lee, Kye Hwa, et al.
Publicado: (2020)

EGFL7 drives the evolution of resistance to EGFR inhibitors in lung cancer by activating NOTCH signaling
por: Wang, Yubo, et al.
Publicado: (2022)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers
por: Wu, Yongxing, et al.
Publicado: (2021)

ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer
por: Roseweir, Antonia K., et al.
Publicado: (2018)

Comment on “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”
por: Uzunparmak, Burak, et al.
Publicado: (2018)

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation
por: Lochhead, Pamela A., et al.
Publicado: (2016)

Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms
por: Su, Xi, et al.
Publicado: (2019)

miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
por: Liu, Szu-Mam, et al.
Publicado: (2014)

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021)

Reply to comment of “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”
por: Roseweir, Antonia K., et al.
Publicado: (2018)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
por: Pickles, Oliver J., et al.
Publicado: (2020)

ERK5 is activated by oncogenic BRAF and promotes melanoma growth
por: Tusa, Ignazia, et al.
Publicado: (2018)

Abl Kinase Regulation by BRAF/ERK and Cooperation with Akt in Melanoma
por: Jain, Aditi, et al.
Publicado: (2017)

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations
por: Lu, Meng-Di, et al.
Publicado: (2022)

Oxidizing to death: Disulfiram for cancer cell killing
por: Brüning, Ansgar, et al.
Publicado: (2014)

A constitutive active MAPK/ERK pathway due to BRAF(V600E) positively regulates AHR pathway in PTC
por: Occhi, Gianluca, et al.
Publicado: (2015)

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer
por: Zaballos, Miguel A., et al.
Publicado: (2022)

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
por: Escuin-Ordinas, Helena, et al.
Publicado: (2016)

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours
por: Paton, Emily L., et al.
Publicado: (2020)

Regulation of BRAF protein stability by a negative feedback loop involving the MEK–ERK pathway but not the FBXW7 tumour suppressor
por: Hernandez, Maria Aguilar, et al.
Publicado: (2016)

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
por: Tutuka, Candani S. A., et al.
Publicado: (2017)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways
por: Ren, Xiaojuan, et al.
Publicado: (2023)

Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways
por: Liu, Yao, et al.
Publicado: (2022)

Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling
por: An, Lei, et al.
Publicado: (2013)

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
por: Ahronian, Leanne G., et al.
Publicado: (2015)

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019)

BIOL-05. MAPK PATHWAY INHIBITION SENSITIZES TO IMMUNOTHERAPY IN BRAF-MUTANT GLIOMAS
por: Park, Jong-Whi, et al.
Publicado: (2021)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers
por: Buffet, Camille, et al.
Publicado: (2017)

Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma
por: Zhao, Kun, et al.
Publicado: (2020)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
por: Bonaldi, Elisa, et al.
Publicado: (2021)

Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners
por: Chiba, Tetsuhiro, et al.
Publicado: (2014)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vn29rmqo205viirkvs53a6tbmg